10-Q: Champions Oncology Reports Q3 Loss Amid Revenue Shift

Champions Oncology reported a net loss for the third quarter and nine months ended January 31, 2026, driven by a significant decline in TOS data license revenue and increased operating expenses.

Summary

• Reported a net loss of $279,000 for the three months ended January 31, 2026, a significant decline from a net income of $4.5 million in the prior-year period.
• For the nine months ended January 31, 2026, the company incurred a net loss of $508,000, compared to a net income of $6.5 million in the same period last year.
• Oncology revenue decreased by 2.8% to $16.6 million for the three months ended January 31, 2026, primarily due to a lack of TOS data license revenue in the current quarter compared to $4.5 million in the prior year.
• Total oncology revenue for the nine months ended January 31, 2026, increased modestly by 2.2% to $45.6 million, but TOS data license revenue dropped from $4.5 million to $0.5 million.
• Operating expenses significantly increased across all categories for both the three and nine-month periods, including a 33.5% rise in cost of oncology revenue for the quarter and a 43.3% increase in research and development for the nine months.
• Cash and cash equivalents decreased to $7.1 million as of January 31, 2026, from $9.8 million at April 30, 2025, with $2.5 million used in operating activities for the nine-month period.
• The company reported negative working capital of $492,000 and an accumulated deficit of $80.4 million as of January 31, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report due to the significant shift from net income to net loss, substantial decline in high-margin data license revenue, and increased cash burn from operations, despite some growth in core pharmacology services.

Positives

• Pharmacology services revenue increased for both the threeand nine-month periods ended January 31, 2026, reflecting modest improvement in bookings and study completion.
• A gain on lease termination of $9,000 was recorded during the three months ended October 31, 2025, due to the early termination of the Italy lease.

Negatives

• Net income shifted to a net loss of $279,000 for the three months and $508,000 for the nine months ended January 31, 2026, compared to significant profits in the prior year periods.
• TOS data license revenue was $0 for the three months ended January 31, 2026, down from $4.5 million in the prior year, and $0.5 million for the nine months, down from $4.5 million.
• Other TOS revenue, including flow cytometry and SaaS, decreased due to lower clinical bookings and a strategic de-emphasis on these areas.
• Cost of oncology revenue increased by 33.5% for the quarter and 14.1% for the nine months, primarily due to outsourced radiolabeling work.
• Research and development expenses rose by 32.1% for the quarter and 43.3% for the nine months, driven by higher outsourced laboratory services and compensation.
• Sales and marketing expenses increased by 47.6% for the quarter and 24.5% for the nine months, due to expansion of the commercial organization.
• General and administrative expenses grew by 24.1% for the quarter and 25.0% for the nine months, attributed to executive leadership changes and increased IT infrastructure costs.
• The company reported negative working capital of $492,000 and used $2.5 million in cash from operating activities for the nine months ended January 31, 2026.

Risks

• Results of operations may be adversely affected by various factors causing economic uncertainty and volatility in financial markets, many of which are beyond the company's control.
• Business could be impacted by downturns in financial markets or economic conditions, increases in oil prices, inflation, increases in interest rates, supply chain disruptions, and declines in consumer confidence and spending.
• The effects of a resurgence or emergence of pandemic-like viruses could negatively impact the business.
• Geopolitical instability, such as military conflicts in Ukraine and the Middle East, poses a risk to the business.

Future Outlook

Management believes that current cash on hand, combined with expected cash flows from operations, will be adequate to fund operations through at least March 2027. The company is regularly evaluating strategic options for its drug discovery business, which may include potential spin-out transactions or capital raises. Management also expects to benefit from a more favorable cost structure as radiolabeling work transitions into Champions laboratories over the coming quarters, and sales and marketing expenses are expected to remain elevated due to continued investment in commercial capabilities.

Management Comments

• "Despite our negative working capital at this date and cash used in operations for the period, we believe that our cash on hand, together with expected cash flows from operations, are adequate to fund operations through at least March 2027."
• "Should the Company be required to raise additional capital, there can be no assurance that management would be successful in raising such capital on terms acceptable to us, if at all."
• "Management expects that as this radiolabeling work transitions into Champions laboratories over the coming quarters, the Company will benefit from a more favorable cost structure."
• "Sales and marketing expenses are expected to remain elevated as the Company continues to invest in commercial capabilities to support these growth initiatives."
• "We regularly evaluate strategic options to create additional value from our drug discovery business, which may include, but are not limited to, potential spin-out transactions or capital raises."

Industry Context

StockSavvy.ai notes that Champions Oncology operates in the highly competitive and capital-intensive oncology drug discovery and development sector. The company's focus on Patient Derived Xenograft (PDX) models and bioinformatics platforms like Lumin aligns with broader industry trends towards personalized medicine and data-driven drug development. The strategic de-emphasis on certain services like flow cytometry suggests a focus on core, higher-value offerings, while increased R&D and sales & marketing expenses indicate continued investment in its primary technology platforms and commercial reach, which is typical for companies aiming for growth in this innovative space.

Related Party Transactions

• During the nine months ended January 31, 2026, the company recognized $0 for consulting services provided by an affiliate of a Board member, compared to $12,000 in the prior year period.

Stakeholder Impact

• Shareholders: Negative impact due to net losses, decreased EPS, negative working capital, and potential future dilution from capital raises.
• Employees: Continued investment in compensation for commercial organization expansion and R&D initiatives, but also potential strategic shifts affecting certain service lines.
• Customers: Continued access to core pharmacology services and data platforms, with a de-emphasis on flow cytometry and other TOS services.
• Creditors: Increased scrutiny due to negative working capital and cash used in operations, though management believes liquidity is adequate for the next 12 months.

Next Steps

• Transition radiolabeling work from third-party laboratories into Champions' own facilities to achieve a more favorable cost structure in coming quarters.
• Continue to invest in commercial capabilities to support growth initiatives in core research services and data licensing.
• Evaluate strategic options for the drug discovery business, potentially including spin-out transactions or capital raises.

Key Dates

Recommendation

The company's significant shift from profitability to a net loss, coupled with a substantial decline in high-margin TOS data license revenue and increased operating expenses, indicates deteriorating financial performance. The negative working capital and cash used in operating activities further highlight liquidity concerns. While management expresses confidence in short-term liquidity, the need to evaluate potential capital raises and the strategic de-emphasis of certain revenue streams suggest underlying challenges. A seasoned investor would likely view these results as a strong negative signal, warranting a 'sell' recommendation given the current financial trajectory and lack of clear positive catalysts.

Keywords

Oncology, Drug Discovery, Biotechnology, Pharmaceutical, Patient Derived Xenograft, PDX Models, TumorGraft, Bioinformatics, SaaS, Lumin, Cancer Research, SEC Filing, 10-Q, Financial Results